BR112022019689A2 - Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer - Google Patents
Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncerInfo
- Publication number
- BR112022019689A2 BR112022019689A2 BR112022019689A BR112022019689A BR112022019689A2 BR 112022019689 A2 BR112022019689 A2 BR 112022019689A2 BR 112022019689 A BR112022019689 A BR 112022019689A BR 112022019689 A BR112022019689 A BR 112022019689A BR 112022019689 A2 BR112022019689 A2 BR 112022019689A2
- Authority
- BR
- Brazil
- Prior art keywords
- cytokine
- masked
- cytokines
- cancer
- kit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003824P | 2020-04-01 | 2020-04-01 | |
| US202063118571P | 2020-11-25 | 2020-11-25 | |
| PCT/US2021/025103 WO2021202675A1 (en) | 2020-04-01 | 2021-03-31 | Masked il-2 cytokines and their cleavage products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019689A2 true BR112022019689A2 (pt) | 2022-12-20 |
Family
ID=77928454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019689A BR112022019689A2 (pt) | 2020-04-01 | 2021-03-31 | Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230151072A1 (https=) |
| EP (1) | EP4126247A4 (https=) |
| JP (1) | JP7735306B2 (https=) |
| KR (1) | KR20220161404A (https=) |
| CN (1) | CN115942976A (https=) |
| AU (1) | AU2021245922A1 (https=) |
| BR (1) | BR112022019689A2 (https=) |
| CA (1) | CA3172649A1 (https=) |
| IL (1) | IL296915A (https=) |
| MX (1) | MX2022012311A (https=) |
| PH (1) | PH12022552627A1 (https=) |
| TW (1) | TW202204388A (https=) |
| WO (1) | WO2021202675A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| WO2021207669A1 (en) * | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| AU2023226005A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| WO2023164286A1 (en) * | 2022-02-28 | 2023-08-31 | Xilio Development, Inc. | Engineered cd122 compositions and methods thereof |
| JP2025508882A (ja) * | 2022-02-28 | 2025-04-10 | エクシリオ デベロップメント， インコーポレイテッド | 標的化サイトカインおよびその使用方法 |
| WO2024015960A1 (en) * | 2022-07-15 | 2024-01-18 | Xilio Development, Inc. | Engineered cleavable fc domain as carriers and methods of use thereof |
| CN117917438A (zh) * | 2022-10-21 | 2024-04-23 | 北京诺诚健华医药科技有限公司 | 抗体融合蛋白及其制备和应用 |
| US20240376170A1 (en) | 2023-01-11 | 2024-11-14 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| TW202517789A (zh) * | 2023-07-04 | 2025-05-01 | 香港商禮邦醫藥（香港）有限公司 | Ｋｌｋ１融合蛋白質的製備方法 |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025049948A1 (en) * | 2023-08-30 | 2025-03-06 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025162454A1 (zh) * | 2024-02-02 | 2025-08-07 | 北京昌平实验室 | 双特异性抗体和细胞因子融合蛋白及其应用 |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| CA2878626A1 (en) * | 2012-08-09 | 2014-02-13 | Roche Glycart Ag | Asgpr antibodies and uses thereof |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| CN108218993B (zh) | 2018-01-05 | 2020-11-17 | 阿思科力(苏州)生物科技有限公司 | 一种以robo1为靶点的双特异性抗体及其制备和应用 |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| AU2019271148B9 (en) * | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| WO2020023702A1 (en) * | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| US20210221864A1 (en) * | 2018-08-24 | 2021-07-22 | City Of Hope | Masked cytokine conjugates |
| US20220002370A1 (en) * | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| US20220227837A1 (en) | 2019-05-24 | 2022-07-21 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
-
2021
- 2021-03-31 TW TW110112016A patent/TW202204388A/zh unknown
- 2021-03-31 WO PCT/US2021/025103 patent/WO2021202675A1/en not_active Ceased
- 2021-03-31 AU AU2021245922A patent/AU2021245922A1/en active Pending
- 2021-03-31 CN CN202180039119.8A patent/CN115942976A/zh active Pending
- 2021-03-31 CA CA3172649A patent/CA3172649A1/en active Pending
- 2021-03-31 IL IL296915A patent/IL296915A/en unknown
- 2021-03-31 PH PH1/2022/552627A patent/PH12022552627A1/en unknown
- 2021-03-31 JP JP2022560205A patent/JP7735306B2/ja active Active
- 2021-03-31 BR BR112022019689A patent/BR112022019689A2/pt unknown
- 2021-03-31 MX MX2022012311A patent/MX2022012311A/es unknown
- 2021-03-31 US US17/995,163 patent/US20230151072A1/en active Pending
- 2021-03-31 KR KR1020227037408A patent/KR20220161404A/ko active Pending
- 2021-03-31 EP EP21780178.6A patent/EP4126247A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3172649A1 (en) | 2021-10-07 |
| AU2021245922A1 (en) | 2022-10-13 |
| US20230151072A1 (en) | 2023-05-18 |
| IL296915A (en) | 2022-12-01 |
| MX2022012311A (es) | 2023-01-05 |
| EP4126247A1 (en) | 2023-02-08 |
| KR20220161404A (ko) | 2022-12-06 |
| CN115942976A (zh) | 2023-04-07 |
| JP7735306B2 (ja) | 2025-09-08 |
| EP4126247A4 (en) | 2024-04-24 |
| WO2021202675A1 (en) | 2021-10-07 |
| JP2023520517A (ja) | 2023-05-17 |
| PH12022552627A1 (en) | 2023-01-04 |
| TW202204388A (zh) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019689A2 (pt) | Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer | |
| BR112022019789A2 (pt) | Citocinas il-15 mascaradas, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, composição farmacêutica, kit e métodos de produção de uma citocina il-15 mascarada e de tratamento ou prevenção de câncer | |
| BR112022019708A2 (pt) | Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer | |
| BR112022019532A2 (pt) | Conjugados de neodegrader | |
| EP4321530A3 (en) | Masked cytokine polypeptides | |
| BR112022014522A2 (pt) | Compostos degradadores, composição farmacêutica, métodos para tratar transtornos, compostos | |
| BR112022003335A2 (pt) | Conjugados de il-2 e métodos de uso para tratar doenças autoimunes | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| ECSP22029777A (es) | Heterociclos bic?clicos como inhibidores de fgfr | |
| BR112021020629A2 (pt) | Compostos bicíclicos | |
| SV2009003305A (es) | Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides | |
| BRPI0617162B8 (pt) | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| MX2009004699A (es) | Compuestos de piridinona. | |
| NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
| BR0317430A (pt) | Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno | |
| BRPI0611620A2 (pt) | mimÉticos de glicocorticàide, mÉtodos de fazÊ-los, composiÇÕes farmacÊuticas e usos dos mesmos | |
| BR112022002196A2 (pt) | Terapia de combinação envolvendo anticorpos contra claudina 18.2 e inibidores de ponto de checagem imunológico para tratamento de câncer | |
| CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
| BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| MX2024010488A (es) | Citocinas dirigidas y metodos de uso de estas. | |
| BRPI0519690A2 (pt) | composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos | |
| BRPI0308606B8 (pt) | compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos | |
| CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| WO2022106902A3 (en) | Benzenesulfonamide derivatives and uses thereof | |
| MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. |